Then, we examined the expression levels of STUB1, YWHAQ, and VEGF in BVZ-responsive subtypes of GBM recurrent patients, as shown in Figure 6F. The expression levels of YWHAQ increased by 160% in BVZ-responsive GBM recurrent patients but decreased by 70% in BVZ-non-responsive GBM recurrent patients after BVZ treatment. The gene discussed is YWHAQ; the disease is glioblastoma.